Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 9/20 | 0.57 |
| ▸ | CDK2 | P24941 | 8/20 | 0.57 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.57 |
| ▸ | CDK5R1 | Q15078 | 6/20 | 0.57 |
| ▸ | PRKACA | P17612 | 4/20 | 0.57 |
| ▸ | GSK3B | P49841 | 4/20 | 0.57 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.57 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.57 |
| ▸ | PRKACG | P22612 | 3/20 | 0.57 |
| ▸ | PRKACB | P22694 | 3/20 | 0.57 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.57 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.57 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.57 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.57 |
| ▸ | CDK9 | P50750 | 2/20 | 0.57 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | HTR2B | P41595 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30507532 | 1.00 | CDK1 (0.57) | CDK1CDK2CDK5CDK5R1PRKACA | |
| SCHEMBL18130895 | 0.81 | HSP90AA1 (0.60) | CDK1CDK2CDK5CDK5R1PRKACA | |
| SCHEMBL28029637 | 0.81 | CYP19A1 (0.56) | ADORA2ASMN1; SMN2MAPK10MEN1LMNA | |
| SCHEMBL30046927 | 0.81 | HSP90AA1 (0.60) | CDK1CDK2CDK5CDK5R1PRKACA | |
| SCHEMBL5803933 | 0.79 | CDK1 (0.58) | CDK1CDK2CDK5CDK5R1PRKACA | |
| SCHEMBL3103196 | 0.78 | PRKACA (0.56) | CDK1CDK2CDK5CDK5R1PRKACA | |
| SCHEMBL5140478 | 0.78 | FEN1 (0.57) | CDK2CDK5CDK5R1PRKACAGSK3B | |
| SCHEMBL1914955 | 0.78 | HSP90AA1 (0.59) | CDK2CDK5CDK5R1PRKACAGSK3B | |
| SCHEMBL21083351 | 0.78 | TGFBR1 (0.47) | CDK2SMN1; SMN2MAPK10MEN1LMNA | |
| SCHEMBL31011602 | 0.78 | CYP19A1 (0.45) | CDK1CDK2CDK5CDK5R1PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112010844-B | Preparation method and application of N- (pyrimidine-2-yl) coumarin-7-amine derivative as protein kinase inhibitor | 中国药科大学 | 2023-07-25 | — | — | CN | disclosed |
| CN-112010844-A | Preparation method and application of N- (pyrimidine-2-yl) coumarin-7-amine derivative as protein kinase inhibitor | 中国药科大学 | 2020-12-01 | — | — | CN | disclosed |
| US-20040242633-A1 | Beta3 adrenergic agonists | EVERS BRITTA (DE) | 2004-12-02 | — | — | US | disclosed |
| US-6730792-B2 | PYRIDINE DERIVATIVES; ANTIDIABETIC, ANTICHOLESTEROL, AND ANTIINFLAMMATORY AGENTS; DECYCLIZATION, DEETHERIFICATION; OBESITY; RAISES HIGH DENSITY LIPOPROTEINS; LOWERS TRIGLYCERIDE LEVELS | ELI LILLY AND COMPANY | 2004-05-04 | — | — | US | disclosed |
| US-20030191156-A1 | Beta3 adrenergic agonists | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2003-10-09 | — | — | US | disclosed |
| CN-1441800-A | β3Adrenergic agonists | LILLY CO ELI (US) | 2003-09-10 | — | — | CN | disclosed |
| EP-1303509-A1 | BETA3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002006276-A1 | BETA3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191156-A1 | Beta3 adrenergic agonists | ADRB3, ADRB1, ADRB2 | CDK1 4819/4885CDK2 4701/4885CDK5 4467/4885 |
| US-20040242633-A1 | Beta3 adrenergic agonists | ADRB3, ADRB1, ADRB2 | CDK1 4692/4885CDK2 4684/4885CDK5 4539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.